Hortobagyi GN - Search Results

1

Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.

Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans W, Van Laere SJ, Bertucci F, Hortobagyi GN, Ueno NT. Masuda H, et al. Among authors: hortobagyi gn. Breast Cancer Res. 2013 Nov 25;15(6):R112. doi: 10.1186/bcr3579. Breast Cancer Res. 2013. PMID: 24274653 Free PMC article.

2

Discouraging news for high-dose chemotherapy in high-risk breast cancer.

Pusztai L, Hortobagyi GN. Pusztai L, et al. Among authors: hortobagyi gn. Lancet. 1998 Aug 15;352(9127):501-2. doi: 10.1016/S0140-6736(05)79310-7. Lancet. 1998. PMID: 9716049 No abstract available.

3

Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer.

Pusztai L, Asmar L, Smith TL, Hortobagyi GN. Pusztai L, et al. Among authors: hortobagyi gn. Breast Cancer Res Treat. 1999 May;55(1):1-8. doi: 10.1023/a:1006161906667. Breast Cancer Res Treat. 1999. PMID: 10472774

4

Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.

Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN. Pusztai L, et al. Among authors: hortobagyi gn. Cancer Treat Rev. 1999 Oct;25(5):271-7. doi: 10.1053/ctrv.1999.0132. Cancer Treat Rev. 1999. PMID: 10544071 Review.

5

Allogeneic peripheral blood progenitor cell transplantation in solid tumors.

Ueno NT, Hortobagyi GN, Champlin RE. Ueno NT, et al. Among authors: hortobagyi gn. Cancer Treat Res. 1999;101:133-56. doi: 10.1007/978-1-4615-4987-1_7. Cancer Treat Res. 1999. PMID: 10800648 Review. No abstract available.

6

Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer.

Hung MC, Hortobagyi GN, Ueno NT. Hung MC, et al. Among authors: hortobagyi gn. Adv Exp Med Biol. 2000;465:171-80. doi: 10.1007/0-306-46817-4_16. Adv Exp Med Biol. 2000. PMID: 10810625 Review. No abstract available.

7

Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.

Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Buchholz TA, et al. Among authors: hortobagyi gn. Cancer J. 2001 Sep-Oct;7(5):413-20. Cancer J. 2001. PMID: 11693900

8

Paclitaxel in the multimodality treatment for inflammatory breast carcinoma.

Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Cristofanilli M, et al. Among authors: hortobagyi gn. Cancer. 2001 Oct 1;92(7):1775-82. doi: 10.1002/1097-0142(20011001)92:7<1775::aid-cncr1693>3.0.co;2-e. Cancer. 2001. PMID: 11745249 Clinical Trial.

9

Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.

Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L. Buchholz TA, et al. Among authors: hortobagyi gn. Cancer J. 2002 Nov-Dec;8(6):461-8. doi: 10.1097/00130404-200211000-00010. Cancer J. 2002. PMID: 12500855

10

Estrogen receptors and distinct patterns of breast cancer relapse.

Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Hess KR, et al. Among authors: hortobagyi gn. Breast Cancer Res Treat. 2003 Mar;78(1):105-18. doi: 10.1023/a:1022166517963. Breast Cancer Res Treat. 2003. PMID: 12611463

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,108 results

Search Page

Filters